uniQure QURE
NASDAQ QURE
$44.50 -0.36 (-0.80%)
As of: Sep 4, 2026 · 3:59 PM EDT

uniQure (QURE) Liabilities and Shareholders Equity (2015 - 2026)

uniQure (QURE) posted quarterly Liabilities and Shareholders Equity of $985.1 million for Q2 2026, up 68.43% year-over-year from $584.9 million in Q2 2025, and up 26.51% quarter-over-quarter from $778.7 million in Q1 2026.

Analysis

uniQure (QURE) Liabilities and Shareholders Equity (2015 - 2026) Analysis & Trends

uniQure's Liabilities and Shareholders Equity history runs 12 years deep, the most recent figure standing at $985.1 million for Q2 2026.

  • In Q2 2026, Liabilities and Shareholders Equity rose 68.43% year-over-year to $985.1 million; the TTM figure through Jun 2026 stood at $3.5 billion (up 45.33% YoY), while the FY2025 annual figure was $824.9 million, up 48.22% from the prior year.
  • Liabilities and Shareholders Equity for Q2 2026 stood at $985.1 million, up from $778.7 million in the prior quarter.
  • The five-year high for Liabilities and Shareholders Equity was $985.1 million in Q2 2026, with the low at $556.5 million in Q4 2024.
  • The 5-year median for Liabilities and Shareholders Equity is $744.0 million (2022), against an average of $747.2 million.
  • The sharpest annual moves came in 2022 and 2024: Liabilities and Shareholders Equity soared 108.09% in 2022, then tumbled 33.08% in 2024.
  • uniQure's Liabilities and Shareholders Equity stood at $705.0 million in 2022, then grew by 17.98% to $831.7 million in 2023, then sank by 33.08% to $556.5 million in 2024, then surged by 48.22% to $824.9 million in 2025, then climbed by 19.42% to $985.1 million in 2026.
  • Business Quant data shows QURE's Liabilities and Shareholders Equity at $985.1 million in Q2 2026, $778.7 million in Q1 2026, and $824.9 million in Q4 2025.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn 10.03 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn 10.96 Bn
5 Revolution Medicines 44.33 Bn 44.33 Bn - 4.32 Bn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 9.18 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 5.56 Bn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 19.82 Bn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 2.10 Bn
10 uniQure 2.95 Bn 2.95 Bn 5.49 Mn 985.10 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 985.10 Mn
Mar 31, 2026 778.71 Mn
Dec 31, 2025 824.91 Mn
Sep 30, 2025 888.38 Mn
Jun 30, 2025 584.89 Mn
Mar 31, 2025 605.40 Mn
Dec 31, 2024 556.54 Mn
Sep 30, 2024 645.81 Mn
Jun 30, 2024 730.85 Mn
Mar 31, 2024 770.05 Mn
Dec 31, 2023 831.69 Mn
Sep 30, 2023 871.55 Mn
Jun 30, 2023 942.77 Mn
Mar 31, 2023 631.00 Mn
Dec 31, 2022 704.96 Mn
Sep 30, 2022 638.23 Mn
Jun 30, 2022 701.21 Mn
Mar 31, 2022 757.15 Mn
Dec 31, 2021 809.18 Mn
Sep 30, 2021 774.63 Mn